¼¼°èÀÇ ´çÁúüÇÐ/´ç¼â»ý¹°ÇÐ ½ÃÀå
Glycomics / Glycobiology
»óǰÄÚµå : 1565035
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 249 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´çÁúüÇÐ/´ç¼â»ý¹°ÇÐ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 64¾ï ´Þ·¯¿¡ ´ÞÇÒ °Í

2023³â 21¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ´çÁúüÇÐ/´ç¼â»ý¹°ÇÐ ¼¼°è ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 16.9% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 64¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ È¿¼Ò ºÎ¹®Àº CAGR 17.8%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 29¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ŰƮ ¹× ½Ã¾à ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 16.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ¾à 5¾ï 9,290¸¸ ´Þ·¯, Áß±¹Àº CAGR 16.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»ó

¹Ì±¹ÀÇ ´çÁúüÇÐ/´ç¼â»ý¹°ÇÐ ½ÃÀåÀº 2023³â 5¾ï 9,290¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 9¾ï 6,640¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 16.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 14.9%¿Í 14.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¾à 12.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ´çÁúüÇÐ/´ç¼â»ý¹°ÇÐ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

´çÁúüÇÐ/´ç¼â»ý¹°ÇÐÀÌ »ý¸í°øÇÐ ¹× ÀÇÇÐÀÇ ÁÖ¿ä ºÐ¾ß·Î ºÎ»óÇϰí ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî¿ä?

´ç»ç½½ »ý¹°ÇÐÀ̶ó°íµµ ºÒ¸®´Â ´çÁúüÇÐÀº º¹ÀâÇÑ »ý¹°ÇÐÀû °úÁ¤À» ÀÌÇØÇϰí Ä¡·á¹ýÀ» ¹ßÀü½ÃŰ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ »ý¸í°øÇÐ ¹× ÀÇÇп¡¼­ ¾ø¾î¼­´Â ¾È µÉ ºÐ¾ß·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ±×·¸´Ù¸é ¿À´Ã³¯ ´çÁúüÇа¡ ¿Ö ÀÌÅä·Ï Áß¿äÇÑ °ÍÀϱî? ´ç¼â»ý¹°ÇÐÀº ´Ü¹éÁú°ú ÁöÁú¿¡ °áÇÕÇÏ¿© ¼¼Æ÷ ½ÅÈ£Àü´Þ, ¸é¿ª¹ÝÀÀ, Áúº´ ÁøÇà µî ´Ù¾çÇÑ »ý¹°ÇÐÀû ±â´É¿¡ °ü¿©ÇÏ´Â º¹ÇÕ ´çÁúÀÎ ´ç¼â¸¦ Á¾ÇÕÀûÀ¸·Î ¿¬±¸ÇÏ´Â Çй®ÀÔ´Ï´Ù. ´ç¼â»ý¹°ÇÐÀº ÀÌ·¯ÇÑ ´çºÐÀÚ°¡ ¼¼Æ÷ °£ ¼ÒÅë, Áúº´ ¸ÞÄ¿´ÏÁò, »õ·Î¿î Áø´Ü ¹× Ä¡·á¹ý °³¹ß¿¡ ¾î¶»°Ô ¿µÇâÀ» ¹ÌÄ¡´ÂÁö¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù.

´ç»ç½½Àº ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ µî Áúº´ÀÇ ÁøÇà¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ´ç¼â»ý¹°ÇÐ ¿¬±¸´Â Àΰ£ÀÇ °Ç°­¿¡ ±¤¹üÀ§ÇÑ Àǹ̸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ´ç »ç½½ÀÇ ±¸Á¶¿Í ±â´ÉÀ» ÇØµ¶ÇÔÀ¸·Î½á Áúº´À» Á¶±â¿¡ Áø´ÜÇϰí, º¸´Ù Ç¥ÀûÈ­µÈ Ä¡·á¹ýÀ» °³¹ßÇϰí, º¸´Ù È¿°úÀûÀÎ ¹é½ÅÀ» °³¹ßÇÒ ¼ö ÀÖ´Â »õ·Î¿î ¹æ¹ýÀ» ¹ß°ßÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´çÁúüÇÐÀº ¾à¹° »óÈ£ ÀÛ¿ëÀ» ÀÌÇØÇÏ°í »ý¹°ÇÐÀû Á¦Á¦¸¦ ¼³°èÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, ÀÌ´Â Á¤¹Ð ÀÇÇп¡¼­ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ Á߿伺ÀÌ Ä¿Áü¿¡ µû¶ó, ´çÁúüÇÐÀº ºÐÀÚ ¼öÁØ¿¡¼­ ½Åü ±â´É¿¡ ´ëÇÑ »õ·Î¿î ÅëÂû·ÂÀ» Á¦°øÇØ Áø´Ü, Ä¡·á ¹× ¹é½Å °³¹ßÀÇ Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô ´çÁúüÇÐÀÇ ¿¬±¸¿Í ÀÀ¿ëÀ» °¡¼ÓÈ­Çϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ´ç »ç½½ÀÇ º¹À⼺À» ÇØµ¶ÇÏ°í »ý¹°ÇÐÀû ½Ã½ºÅÛ¿¡¼­ ´Ù¾çÇÑ ±â´ÉÀ» ¹àÈú ¼ö ÀÖ°Ô ÇÏ¿© ´çÁúüÇÐ ¿¬±¸¸¦ ÃßÁøÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¹ßÀü Áß Çϳª´Â Áú·® ºÐ¼®(MS) ¹× ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ(LC)¿Í °°Àº °í󸮷® ´ç¼â ºÐ¼® ±â¼úÀÇ °³¹ß·Î ´ç¼â ±¸Á¶ÀÇ ½Å¼ÓÇÑ ½Äº° ¹× Ư¼º ºÐ¼®ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸¸¦ ÅëÇØ ¿¬±¸ÀÚµéÀº »ý¹°Ã¼ ¶Ç´Â Á¶Á÷ ³» Àüü ´ç¼âÀÎ ±Û¸®Ä­(glycome)À» Àü·Ê ¾øÀÌ ºü¸£°í Á¤È®ÇÏ°Ô ¸ÅÇÎÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ´É·ÂÀº ±Û¸®ÄÄÀÌ Á¶Á÷, °³ÀÎ, Áúȯ¿¡ µû¶ó ¾î¶»°Ô ´Ù¸¥Áö ÀÌÇØÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á¹ýÀ» À§ÇÑ ±æÀ» ¿­¾îÁÙ ¼ö ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ±â¼ú ¹ßÀüÀº ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º µµ±¸¸¦ ´çÁúüÇÐ ¿¬±¸¿¡ Àû¿ëÇÏ´Â °ÍÀÔ´Ï´Ù. ¼ö¸¹Àº ºÐÁö¿Í ´Ù¾çÇÑ ±¸¼ºÀ» °¡Áø ´ç¼â ±¸Á¶ÀÇ º¹À⼺Àº ºÐ¼®°ú ÇØ¼®À» À§ÇÑ °íµµÀÇ °è»ê ±â¹ýÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ¸Ó½Å·¯´×°ú ÀΰøÁö´É(AI)ÀÇ ¹ßÀüÀ¸·Î ´ç¼â ±¸Á¶¿Í ´Ü¹éÁú ¹× ÁöÁú°úÀÇ »óÈ£ÀÛ¿ëÀ» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ¾Ë°í¸®ÁòÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ »ý¹°Á¤º¸ÇÐ µµ±¸´Â ¿¬±¸ÀÚµéÀÌ Áúº´ÀÇ ´ç¼â ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°Çϰí, ´ç¼â ±â¹Ý Ä¡·áÁ¦¸¦ °³¹ßÇϸç, ´ç¼âÀÇ º¯È­°¡ Áúº´ ÁøÇà¿¡ ¾î¶»°Ô °ü¿©ÇÏ´ÂÁö ¹àÈ÷´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖÀ¸¸ç, AI ±â¹Ý ºÐ¼®À» ÅëÇØ °úÇÐÀÚµéÀº ¹æ´ëÇÑ ¾çÀÇ ´ç¼â µ¥ÀÌÅ͸¦ ¼±º°ÇÒ ¼ö ÀÖÀ¸¸ç, ÆÐÅϰú ÀáÀçÀû Ä¡·á Ç¥ÀûÀ» º¸´Ù È¿À²ÀûÀ¸·Î ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÇÕ¼º ´ç¼â»ý¹°ÇÐÀÇ ¹ßÀüÀº ÇÕ¼º ´ç¼âÀÇ ¼³°è¿Í Á¦Á¶¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ÀÌ ºÐ¾ß¿¡µµ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÕ¼º ´ç¼â´Â ÀÚ¿¬¿¡ Á¸ÀçÇÏ´Â ºÐÀÚ¸¦ ¸ð¹æÇÏ¿© ¹é½Å °³¹ß, ½Å¾à °³¹ß, Ä¡·á ¿¬±¸¿¡ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿¬±¸ÀÚµéÀº º´¿øÃ¼°¡ Àΰ£ ¼¼Æ÷¿Í ¾î¶»°Ô »óÈ£ÀÛ¿ëÇÏ´ÂÁö ¿¬±¸Çϰųª °­·ÂÇÑ ¸é¿ª ¹ÝÀÀÀ» À¯¹ßÇÏ´Â ¹é½ÅÀ» °³¹ßÇϱâ À§ÇØ Æ¯Á¤ ´ç¼â ±¸Á¶¸¦ ¸¸µé¾î³¾ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ´É·ÂÀº ´ç¼â°¡ ¸é¿ª ȸÇÇ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â µ¶°¨À̳ª Äڷγª¹ÙÀÌ·¯½º¿Í °°Àº º¹ÀâÇÑ ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¹é½ÅÀ» °³¹ßÇÏ´Â µ¥ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ÇÕ¼º ´ç¼â´Â ¾Ï¼¼Æ÷ÀÇ Æ¯Á¤ ¼ö¿ëü¸¦ Ç¥ÀûÀ¸·Î »ï°Å³ª ¸é¿ª ¹ÝÀÀÀ» Á¶ÀýÇÏ´Â ´ç¼â ±â¹Ý ¾à¹°ÀÇ °³¹ß¿¡ Ȱ¿ëµÇ¾î Á¤¹Ð ÀÇÇÐÀÇ »õ·Î¿î ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ ¹ßÀü ºÐ¾ß´Â ±ØÀú¿Â ÀüÀÚ Çö¹Ì°æ(cryoEM) ¹× ´ç¼â ¾î·¹ÀÌ ±â¼ú°ú °°Àº ÷´Ü À̹Ì¡ ±â¼úÀÇ È°¿ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ´ç¼â°¡ ´Ù¸¥ »ýü ºÐÀÚ¿Í ¾î¶»°Ô »óÈ£ ÀÛ¿ëÇÏ´ÂÁö¸¦ ºÐÀÚ ¼öÁØ¿¡¼­ ½Ã°¢È­ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ´Â ¼¼Æ÷ ½ÅÈ£ Àü´Þ, º´¿øÃ¼ ÀνÄ, ¸é¿ª°è ±â´É µîÀÇ °úÁ¤¿¡¼­ ´ç¼âÀÇ ¿ªÇÒÀ» ÀÌÇØÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ´ç¼â ¾î·¹ÀÌ´Â ´Ü¹éÁú°úÀÇ ´ç¼â »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ ³ôÀº 󸮷® ½ºÅ©¸®´×À» °¡´ÉÇÏ°Ô ÇÏ¿© ¾ÏÀ̳ª ½Å°æ ÅðÇ༺ Áúȯ°ú °°Àº Áúº´¿¡ ´ëÇÑ ÀáÀçÀûÀÎ ½Å¾à Ÿ°Ù°ú ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¹àÇô³¾ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À̹Ì¡ ¹× ½ºÅ©¸®´× ±â¼úÀº °Ç°­°ú Áúº´¿¡¼­ ´ç¼âÀÇ ¿ªµ¿ÀûÀÎ ¿ªÇÒ¿¡ ´ëÇÑ ´õ ±íÀº ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.

Áúº´ ±âÀü ±Ô¸í, Áø´Ü¾à °³¹ß, Ä¡·á¹ý ¹ßÀü¿¡ ´çÁúüÇа¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀϱî?

´ç»ç½½Àº »ý¹°ÇÐÀû °úÁ¤°ú Áúº´ÀÇ ÁøÇàÀ» Á¶ÀýÇÏ´Â µ¥ ±âº»ÀûÀÎ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ´çÁúüÇÐÀº Áúº´ ¸ÞÄ¿´ÏÁòÀÇ ÀÌÇØ, Áø´Ü¹ý °³¹ß ¹× Ä¡·á¹ý ¹ßÀü¿¡ ÇʼöÀûÀÔ´Ï´Ù. ´ç »ç½½Àº ´Ü¹éÁúÀÇ Á¢Èû°ú ¾ÈÁ¤¼º¿¡¼­ ¸é¿ª ü°è Ȱ¼ºÈ­¿Í ¼¼Æ÷ °£ Åë½Å¿¡ À̸£±â±îÁö ¼¼Æ÷ ±â´ÉÀÇ °ÅÀÇ ¸ðµç Ãø¸é¿¡ °ü¿©ÇÕ´Ï´Ù. ´ç¼â ±¸Á¶ÀÇ º¯È­´Â Á¾Á¾ Áúº´ »óÅÂ¿Í °ü·ÃÀÌ ÀÖÀ¸¸ç, ´çÁúüÇÐÀº ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ°í ºÐÀÚ ¼öÁØ¿¡¼­ Áúº´ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇÏ´Â µ¥ ±ÍÁßÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

´çÈ­¹°ÀÌ ÀÇÇп¡ ±â¿©ÇÏ´Â °¡Àå Áß¿äÇÑ °øÇå Áß Çϳª´Â Áúº´ÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¹ß°ßÇÏ´Â ´É·ÂÀÔ´Ï´Ù. ±Û¸®ÄÚ ½ÇÈ­(´ç »ç½½ÀÌ ´Ü¹éÁú°ú ÁöÁú¿¡ °áÇÕÇÏ´Â °úÁ¤)ÀÇ º¯È­´Â ¾Ï, ´ç´¢º´, °¨¿°¼º Áúȯ°ú °°Àº Áúº´¿¡¼­ ÀÚÁÖ °üÂûµË´Ï´Ù. ¿¹¸¦ µé¾î, ºñÁ¤»óÀûÀÎ ´ç¼â ÆÐÅÏÀº ¾Ï¼¼Æ÷ÀÇ Æ¯Â¡À̸ç, Á¾¾ç ¼ºÀå, ÀüÀÌ ¹× ¸é¿ª ȸÇǸ¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­µÈ ´ç¼â ½Ã±×´Ïó¸¦ ½Äº°ÇÔÀ¸·Î½á ¿¬±¸ÀÚµéÀº º¸´Ù ¹Î°¨ÇÏ°í Æ¯ÀÌÀûÀÎ Áø´Ü Å×½ºÆ®¸¦ °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ç¼â ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿´Â Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖÀ¸¸ç, ÀÓ»óÀÇ´Â ¾Ï, °£ Áúȯ, ½Å°æ ÅðÇ༺ Áúȯ°ú °°Àº Áúº´À» Ä¡·á °¡´É¼ºÀÌ ³ôÀº Ãʱ⿡ Áø´ÜÇÒ ¼ö ÀÖ°Ô µË´Ï´Ù.

Ä¡·á¿¡ À־ ´çÁúüÇÐÀº º¸´Ù Ç¥ÀûÈ­µÇ°í È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ´ç¼â ±¸Á¶´Â ƯÈ÷ ºñÁ¤»óÀûÀÎ ±Û¸®ÄÚ½ÇÈ­°¡ °ü·ÃµÈ Áúº´¿¡¼­ ¾à¹°ÀÇ Ç¥ÀûÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ÀϺΠ¾ÏÀº Ç¥¸é ´Ü¹éÁú¿¡ ƯÀÌÀûÀÎ ´ç¼â ÆÐÅÏÀ» º¸À̴µ¥, ´çÁúüÇÐ ¿¬±¸´Â ÀÌ·¯ÇÑ ºñÁ¤»óÀûÀÎ ´ç¼â¸¦ ƯÀÌÀûÀ¸·Î Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´ç¼â¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·á´Â °Ç°­ÇÑ Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 º´º¯ ¼¼Æ÷¿¡ ÃÊÁ¡À» ¸ÂÃß´Â º¸´Ù Á¤¹ÐÇÑ Ä¡·á Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù. ´çÁúüÇÐÀº ¶ÇÇÑ º´¿øÃ¼ ¹× ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ¸é¿ª ÀνÄÀ» Çâ»ó½ÃŰ´Â ´ç¼â ±â¹Ý ¹é½ÅÀÇ ¼³°è¿¡µµ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ´ç¼â´Â ¸é¿ª ü°è°¡ ¿ÜºÎ ÀûÀ» ½Äº°ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ÇÕ¼º ´ç¼â¸¦ ÅëÇÕÇÑ ¹é½ÅÀº º¸´Ù °­·ÂÇÏ°í Æ¯ÀÌÀûÀÎ ¸é¿ª ¹ÝÀÀÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù.

´ç»ç½½ °øÇÐÀº ´ÜŬ·Ð Ç×ü, À¯ÀüÀÚ Ä¡·áÁ¦, ¼¼Æ÷ ±â¹Ý Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ ¼ºÀå ÁßÀÎ Ä¡·á¿ë »ý¹°ÇÐÀû Á¦Á¦ °³¹ß¿¡µµ ÇʼöÀûÀÔ´Ï´Ù. Ä¡·á¿ë Ç×ü¿Í °°Àº ¸¹Àº »ý¹°ÇÐÀû Á¦Á¦´Â ¾ÈÁ¤¼º, È¿´É ¹× ¾ÈÀü¼ºÀ» À§ÇØ ±Û¸®ÄÚ½ÇÈ­¿¡ ÀÇÁ¸ÇÕ´Ï´Ù. ´çÁúüÇÐ(Glycomics)´Â Á¦Á¶ °úÁ¤¿¡¼­ ±Û¸®ÄÚ½ÇÈ­ ÆÐÅÏÀ» ÀÌÇØÇϰí Á¦¾îÇÏ´Â °ÍÀº »ý¹°ÇÐÀû Á¦Á¦°¡ Á¦´ë·Î ÀÛµ¿Çϰí ȯÀÚ¿¡°Ô ¾ÈÀüÇÑÁö È®ÀÎÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ´çÁúüÇÐÀº Á¦Á¶ °úÁ¤¿¡¼­ ±Û¸®ÄÚ½ÇÈ­¸¦ ¸ð´ÏÅ͸µÇϰí ÃÖÀûÈ­ÇÏ´Â µ¥ ÇÊ¿äÇÑ µµ±¸¸¦ Á¦°øÇÏ¿© Á¦¾à»ç°¡ º¸´Ù È¿°úÀûÀ̰í Àϰü¼º ÀÖ°Ô »ý¹°ÇÐÀû Á¦Á¦¸¦ °³¹ßÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. º¸´Ù È¿°úÀûÀ̰í Àϰü¼º ÀÖ´Â »ý¹°ÇÐÀû Á¦Á¦¸¦ °³¹ßÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

Ä¡·áÁ¦¿Í Áø´ÜÁ¦ ¿Ü¿¡µµ ´çÁúüÇÐÀº °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀü¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ´ç¼â ÆÐÅÏÀº À¯ÀüÀû, ȯ°æÀû ¿äÀο¡ µû¶ó °³Àθ¶´Ù ´Ù¸¦ ¼ö Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ º¯È­¸¦ ÀÌÇØÇϸé ȯÀÚº° ´ç¼â ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â ¸ÂÃãÇü Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â Á¾¾çÀÌ Á¾Á¾ ƯÀÌÀûÀÎ ´ç¼â ÆÐÅÏÀ» º¸ÀÌ´Â ¾Ï¿¡¼­ ƯÈ÷ Áß¿äÇϸç, ÀÌ´Â ¸ÂÃã Ä¡·áÀÇ Ç¥ÀûÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ´çÁúüÇÐ ºÐ¾ß°¡ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó, ȯÀÚ °³°³ÀÎÀÇ ºÐÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá º¸´Ù È¿°úÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí, Á¤¹ÐÀÇ·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ°Ô µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

´çÁúüÇÐ/´ç¼â»ý¹°ÇÐ ½ÃÀåÀÇ ¼ºÀå µ¿·ÂÀº ¹«¾ùÀϱî?

´çÁúüÇÐ/´ç¼â»ý¹°ÇÐ ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀå¿¡´Â ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀǾàǰ °³¹ßÀÇ ¹ßÀü, º¹ÀâÇÑ Áúº´ÀÇ À¯º´·ü Áõ°¡, ´ç¼â ºÐ¼®ÀÇ ±â¼ú Çõ½Å µî ¸î °¡Áö ÁÖ¿ä ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ù°, °³ÀÎ ¸ÂÃãÇü ÀÇ·áÀÇ ÃßÁøÀº ´çÁúüÇÐ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÇコÄɾ ȹÀÏÀûÀÎ Á¢±Ù ¹æ½Ä¿¡¼­ º¸´Ù ¸ÂÃã Ä¡·á·Î ÀüȯµÇ°í ÀÖ´Â °¡¿îµ¥, ´çÁúüÇÐÀº Ä¡·áÀÇ °³º°È­¿¡ Ȱ¿ëÇÒ ¼ö ÀÖ´Â °íÀ¯ÇÑ ´ç¼â ÇÁ·ÎÆÄÀÏÀ» ½Äº°ÇÏ´Â µµ±¸¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ´Â ¾Ï¼¼Æ÷°¡ Á¾Á¾ ƯÀÌÀûÀÎ ´ç¼â º¯È­¸¦ º¸ÀÌ´Â Á¾¾çÇп¡¼­ ƯÈ÷ Áß¿äÇϸç, º¸´Ù È¿°úÀûÀÎ Ä¡·áÀÇ Ç¥ÀûÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃã Ä¡·á Àü·«À» À§ÇØ ´ç¼â ¹ÙÀÌ¿À¸¶Ä¿¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ¿¬±¸ ¹× ÀÓ»ó ÇöÀå¿¡¼­ ´çÁúüÇÐ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

µÑ°, ÀǾàǰ °³¹ß, ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦ ¹× ´ÜÀÏ Å¬·Ð Ç×ü ºÐ¾ßÀÇ ¹ßÀüÀÌ ´çÁúüÇÐ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº »ý¹°ÇÐÀû Á¦Á¦´Â Ȱ¼º, ¾ÈÁ¤¼º ¹× ¾ÈÀü¼ºÀ» À§ÇØ ´ç¼â º¯Çü¿¡ ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á¹ýÀ» ¸¸µé±â À§Çؼ­´Â ¾à¹° Á¦Á¶ ½Ã ÀÌ·¯ÇÑ ´ç¼â ±¸Á¶¸¦ Á¦¾îÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù. Á¦¾àȸ»çµéÀº »ý¹°ÇÐÀû Á¦Á¦ÀÇ ±Û¸®ÄÚ½ÇÈ­¸¦ ÃÖÀûÈ­Çϰí ÀÌ·¯ÇÑ Ä¡·áÁ¦°¡ ÃÖ°í ¼öÁØÀÇ È¿´É°ú ¾ÈÀü¼ºÀ» ÃæÁ·ÇÒ ¼ö ÀÖµµ·Ï ´çÁúüÇÐ µµ±¸¿Í ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀǾàǰ °³¹ßÀÇ ÀÌ·¯ÇÑ Á¤¹Ð¼º¿¡ ´ëÇÑ ¿ä±¸´Â Á¦¾à »ê¾÷¿¡¼­ ´çÁúüÇÐÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼Â°, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ½Å°æÅðÇ༺ Áúȯ°ú °°Àº º¹ÀâÇÑ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °í±Þ Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´çÁúüÇÐÀº ´ç¼âÀÇ º¯È­°¡ Áúº´ ÁøÇà¿¡ ¾î¶»°Ô °ü¿©ÇÏ´ÂÁö¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¼ö¿ä¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â µ¶º¸ÀûÀÎ À§Ä¡¿¡ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ´ç¼â ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿´Â ¾ÏÀÇ Á¶±â ¹ß°ßÀ» À§ÇØ °³¹ßµÇ°í ÀÖÀ¸¸ç, ´ç¼â¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·á¹ýÀº ÀÚ°¡¸é¿ªÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ »õ·Î¿î Ä¡·á¹ýÀ¸·Î ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ÀÌ·¯ÇÑ Áúº´¿¡ ´ëÇÑ ºÎ´ãÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó, ´çÁúüÇÐ ±â¹Ý ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä´Â Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ç¼â ºÐ¼®ÀÇ ±â¼ú Çõ½Åµµ ´çÁúüÇÐ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. Áú·® ºÐ¼®, ´ç¼â ¾î·¹ÀÌ ¹× »ý¹°Á¤º¸ÇÐ µµ±¸ÀÇ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµéÀº ´õ ºü¸£°í, ´õ Á¤È®Çϰí, ´õ ³ôÀº ÇØ»óµµ·Î ´ç¼â¸¦ ºÐ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ °úÇÐÀÚµéÀº ±Û¸®ÄÞÀ» ¸ÅÇÎÇϰí, Áúº´¿¡ ƯȭµÈ ´ç¼â º¯È­¸¦ ½Äº°Çϰí, »õ·Î¿î ´ç¼â ±â¹Ý Ä¡·á¹ýÀ» ½±°Ô °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °í󸮷® ´ç¼â ºÐ¼® µµ±¸ÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¿¬±¸°¡ °¡¼ÓÈ­µÇ°í Áø´Ü, Ä¡·á, ¹é½Å °³¹ß µîÀÇ ºÐ¾ß¿¡¼­ ´çÁúüÇÐÀÇ »ó¾÷Àû ÀáÀç·ÂÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ´çÁúüÇÐ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡¿Í Àü¹® ´çÁúüÇÐ ¿¬±¸¼¾ÅÍÀÇ ¼³¸³ÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ, Çаè, ºñ»óÀå ±â¾÷µéÀº ´çÁúüÇÐ ¿¬±¸¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÇコÄɾ º¯È­¸¦ °¡Á®¿Ã ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. Çаè, »ê¾÷°è, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù·ÂÀû ³ë·ÂÀ¸·Î ´çÁúüÇÐÀÇ ÀÓ»ó Àû¿ëÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ´çÁúüÇÐ µµ±¸ ¹× ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

°á·ÐÀûÀ¸·Î, ´çÁúüÇÐ/´ç»çü »ý¹°ÇÐ ½ÃÀåÀÇ ¼ºÀåÀº °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀǾàǰ °³¹ßÀÇ ¹ßÀü, º¹ÀâÇÑ Áúº´ÀÇ À¯º´·ü Áõ°¡, ±×¸®°í ´çÁúüÇÐ ºÐ¼®ÀÇ ±â¼ú Çõ½Å¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´çÁúüÇа¡ °Ç°­°ú Áúº´¿¡¼­ ´ç »ç½½ÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ´õ ±íÀº ÅëÂû·ÂÀ» Á¦°øÇÔ¿¡ µû¶ó ´Ù¾çÇÑ ÀÇ·á ¹× »ê¾÷ ÀÀ¿ë ºÐ¾ß¿¡¼­ Áø´Ü, Ä¡·á ¹× Á¤¹ÐÀÇ·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ°Ô µÉ °ÍÀÔ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 152°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Glycomics / Glycobiology Market to Reach US$6.4 Billion by 2030

The global market for Glycomics / Glycobiology estimated at US$2.1 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2023-2030. Enzymes, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Kits & Reagents segment is estimated at 16.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$592.9 Million While China is Forecast to Grow at 16.0% CAGR

The Glycomics / Glycobiology market in the U.S. is estimated at US$592.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$966.4 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Glycomics / Glycobiology Market - Key Trends and Drivers Summarized

Why Is Glycomics/Glycobiology Emerging as a Key Field in Biotechnology and Medicine?

Glycomics, also referred to as glycobiology, is becoming an essential field in biotechnology and medicine due to its critical role in understanding complex biological processes and advancing therapeutic solutions. But why is glycomics so vital today? Glycomics is the comprehensive study of glycans—complex carbohydrates that attach to proteins and lipids and are involved in a wide variety of biological functions, including cell signaling, immune response, and disease progression. Glycobiology focuses on how these sugar molecules influence cellular communication, disease mechanisms, and the development of new diagnostics and treatments.

The study of glycomics has far-reaching implications for human health, as glycans play a crucial role in the progression of diseases such as cancer, autoimmune disorders, and infections. By decoding the structure and function of glycans, researchers are uncovering new ways to diagnose diseases earlier, develop more targeted therapies, and create more effective vaccines. Moreover, glycomics is critical for understanding drug interactions and designing biologics, which are rapidly becoming essential tools in precision medicine. As the importance of personalized healthcare grows, glycomics is helping to unlock new insights into how the body functions at a molecular level, driving innovation in diagnostics, therapeutics, and vaccine development.

How Are Technological Advancements Accelerating Research and Applications in Glycomics?

Technological advancements are playing a pivotal role in advancing glycomics research, making it possible to decode the complexities of glycans and uncover their diverse functions in biological systems. One significant advancement is the development of high-throughput glycan analysis techniques, such as mass spectrometry (MS) and liquid chromatography (LC), which allow for the rapid identification and characterization of glycan structures. These tools enable researchers to map the glycome—the entire set of glycans in an organism or tissue—faster and with greater accuracy than ever before. This capability is crucial for understanding how glycans differ across tissues, individuals, or disease states, paving the way for more personalized medical treatments.

Another key technological advancement is the application of bioinformatics tools to glycomics research. The complexity of glycan structures, with their numerous branches and diverse configurations, requires sophisticated computational methods for analysis and interpretation. Advances in machine learning and artificial intelligence (AI) are enabling the development of algorithms that can predict glycan structures and their interactions with proteins and lipids. These bioinformatics tools help researchers identify glycan biomarkers for diseases, develop glycan-based therapeutics, and uncover how glycan alterations contribute to disease progression. With AI-driven analytics, scientists can sift through vast amounts of glycomic data to identify patterns and potential therapeutic targets more efficiently.

Advances in synthetic glycobiology are also transforming the field by enabling the design and production of synthetic glycans. These synthetic glycans mimic naturally occurring molecules and are used in vaccine development, drug discovery, and therapeutic research. For instance, researchers can create specific glycan structures to study how pathogens interact with human cells or to develop vaccines that elicit strong immune responses. This capability is particularly important for developing vaccines for complex viruses like influenza and coronaviruses, where glycans play a key role in immune evasion. Additionally, synthetic glycans are being used in the development of glycan-based drugs that target specific receptors on cancer cells or modulate immune responses, opening new avenues for precision medicine.

Another area of advancement is the use of advanced imaging techniques, such as cryo-electron microscopy (cryo-EM) and glycan array technology. These tools allow scientists to visualize how glycans interact with other biomolecules at the molecular level. This is crucial for understanding the role of glycans in processes like cell signaling, pathogen recognition, and immune system function. Glycan arrays, for example, enable the high-throughput screening of glycan interactions with proteins, which can reveal potential drug targets or biomarkers for diseases like cancer and neurodegenerative disorders. These imaging and screening technologies are providing deeper insights into the dynamic role of glycans in health and disease.

Why Is Glycomics Critical for Understanding Disease Mechanisms, Developing Diagnostics, and Advancing Therapeutics?

Glycomics is critical for understanding disease mechanisms, developing diagnostics, and advancing therapeutics because glycans play a fundamental role in regulating biological processes and disease progression. Glycans are involved in nearly every aspect of cellular function, from protein folding and stability to immune system activation and cell-cell communication. Alterations in glycan structures are often associated with disease states, making glycomics an invaluable tool for identifying biomarkers and understanding disease mechanisms at a molecular level.

One of the most important contributions of glycomics to medicine is its ability to uncover biomarkers for early disease detection. Changes in glycosylation—the process by which glycans attach to proteins or lipids—are frequently observed in diseases like cancer, diabetes, and infectious diseases. For example, abnormal glycan patterns are a hallmark of cancer cells, where they can promote tumor growth, metastasis, and immune evasion. By identifying these altered glycan signatures, researchers can develop more sensitive and specific diagnostic tests. Glycan-based biomarkers hold the potential to revolutionize early disease detection, allowing clinicians to diagnose conditions like cancer, liver disease, and neurodegenerative disorders at earlier stages, when treatments are more likely to be effective.

In therapeutics, glycomics is enabling the development of more targeted and effective treatments. Glycan structures can serve as drug targets, particularly in diseases where abnormal glycosylation is involved. For instance, certain cancers exhibit unique glycan patterns on their surface proteins, and glycomics research is leading to the development of therapies that specifically target these aberrant glycans. These glycan-targeting therapies offer a more precise approach to treatment, minimizing damage to healthy tissues while focusing on the diseased cells. Glycomics is also contributing to the design of glycan-based vaccines that enhance immune recognition of pathogens or cancer cells. Glycans play a crucial role in how the immune system identifies foreign invaders, and vaccines that incorporate synthetic glycans can trigger stronger and more specific immune responses.

Glycomics is also essential for the development of biologics, a growing class of therapeutics that includes monoclonal antibodies, gene therapies, and cell-based treatments. Many biologics, such as therapeutic antibodies, rely on glycosylation for their stability, efficacy, and safety. Understanding and controlling glycosylation patterns during drug manufacturing is critical for ensuring that biologics function correctly and are safe for patients. Glycomics provides the tools needed to monitor and optimize glycosylation during production, helping pharmaceutical companies develop more effective and consistent biologic therapies.

In addition to therapeutics and diagnostics, glycomics is playing a pivotal role in advancing personalized medicine. Since glycan patterns can vary between individuals based on genetic and environmental factors, understanding these variations allows for the development of personalized treatments tailored to a patient’s specific glycan profile. This is particularly important in cancer, where tumors often exhibit unique glycosylation patterns that can be targeted with personalized therapies. As the field of glycomics continues to evolve, it will play an increasingly important role in shaping the future of precision medicine, enabling more effective treatments that are customized to individual patients’ molecular profiles.

What Factors Are Driving the Growth of the Glycomics/Glycobiology Market?

Several key factors are driving the rapid growth of the glycomics/glycobiology market, including the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. First, the push toward personalized medicine is a major driver of the glycomics market. As healthcare shifts from a one-size-fits-all approach to more individualized treatments, glycomics offers the tools to identify unique glycan profiles that can be used to tailor therapies. This is particularly important in oncology, where cancer cells often exhibit specific glycan changes that can be targeted for more effective treatments. The ability to use glycan biomarkers for early disease detection and personalized treatment strategies is fueling the demand for glycomics technologies in research and clinical settings.

Second, advancements in drug development, particularly in the field of biologics and monoclonal antibodies, are contributing to the growth of the glycomics market. Many biologic drugs rely on glycosylation for their activity, stability, and safety, and controlling these glycan structures during drug production is essential for creating effective therapies. Pharmaceutical companies are increasingly investing in glycomics tools and technologies to optimize glycosylation in biologics, ensuring that these therapies meet the highest standards for efficacy and safety. This demand for precision in drug development is driving the adoption of glycomics in the pharmaceutical industry.

Third, the growing prevalence of complex diseases, such as cancer, autoimmune disorders, and neurodegenerative diseases, is increasing the need for advanced diagnostic and therapeutic solutions. Glycomics is uniquely positioned to address this need by offering insights into how changes in glycosylation contribute to disease progression. For example, glycan-based biomarkers are being developed for the early detection of cancers, while glycan-targeting therapies are being explored as novel treatments for autoimmune diseases and infectious diseases. As the global burden of these diseases continues to rise, the demand for glycomics-based solutions is expected to grow significantly.

Technological innovations in glycan analysis are also driving the expansion of the glycomics market. Advances in mass spectrometry, glycan arrays, and bioinformatics tools are enabling researchers to analyze glycans with greater speed, accuracy, and resolution. These technologies are making it easier for scientists to map the glycome, identify disease-specific glycan alterations, and develop new glycan-based therapies. The growing availability of high-throughput glycan analysis tools is accelerating research and expanding the commercial potential of glycomics in fields such as diagnostics, therapeutics, and vaccine development.

Additionally, increased funding for glycomics research and the establishment of specialized glycomics research centers are contributing to market growth. Governments, academic institutions, and private companies are investing heavily in glycomics research due to its potential to transform healthcare. Collaborative efforts between academia, industry, and healthcare providers are advancing the application of glycomics in clinical practice, further driving demand for glycomics tools and technologies.

In conclusion, the growth of the glycomics/glycobiology market is being driven by the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. As glycomics continues to provide deeper insights into the role of glycans in health and disease, it will play a crucial role in shaping the future of diagnostics, therapeutics, and precision medicine across a wide range of medical and industrial applications.

Select Competitors (Total 152 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â